Skip to main content
Insights into Imaging

Table 5 Results of base case analysis* as the difference between usual care and applying the AI tool

From: Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessment

 

Incremental costs ($)

Incremental efficacy (QALYs)

Population

Patient

% of usual care

Population

Patient

% of usual care

Acute phase (< 90 days)

$4,295,152

$60

0.60

9.45

0.0001

0.06

Rest of life phase (> 90 days)

− $15,510,277

− $216

− 0.36

672.82

0.0094

0.07

Total

− $11,215,125

− $156

− 0.23

682.27

0.0095

0.07

  1. *Base case parameters: missed LVOs, 6%; costs per analysis, $40; reduction of missed LVOs, 50%
  2. QALY, quality-adjusted life-year
  3. Costs are rounded to the nearest integer
Back to article page